A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A phase 1/2 trial of A2B694 in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer and mesothelioma, run by A2 Biotherapeutics Inc., now recruiting.
Overview
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression is a phase 1/2 interventional study registered as NCT06051695 by A2 Biotherapeutics Inc., with 474 participants planned, started 2024-04-03 and due to reach its primary completion in 2028-06. Interventions recorded: A2B694 and A2B543.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Shares Tempus AI, Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.